UFP Technologies, Inc. (UFPT) AI Stock Analysis

Established in 1963 and headquartered in Newburyport, Massachusetts, UFP Technologies, Inc. specializes in the design and custom manufacture of components, subassemblies, products, and packaging using specialized foams, films, and plastics. Its primary focus is the medical market, offering single-use devices, disposable wound care, infection prevention solutions, minimally invasive surgery tools, wearable devices, orthopedic soft goods, and implant packaging. Beyond healthcare, it supplies engineered products for automotive interior trim, aerospace and defense gear, consumer goods, electronics, and industrial protective packaging. UFP Technologies serves customers primarily in the United States through direct sales and independent manufacturer representatives.

Revenue expanded from $206.3M in FY2021 to $602.8M in FY2025, representing a 5-year revenue CAGR of 27.4%. Over the same timeframe, gross margin rose from 24.8% to 28.3%, and net income increased from $15.9M to $68.3M, lifting annual diluted EPS from $2.10 to $9.80. Operating margin finished at 15.3% in FY2025 after peaking at 16.0% in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $631.6M with a profit margin of 11.5% and EPS of $9.26. In the latest quarter ended June 30, 2026, quarterly revenue grew 15.1% year-over-year while quarterly earnings expanded 21.3%.

As of June 30, 2026, UFP Technologies held $9.0M in cash and short-term investments against $136.3M in total debt, resulting in net debt of $127.3M. The company reported shareholders' equity of $462.4M and total assets of $681.9M, supporting a debt-to-equity ratio of 0.29 and a current ratio of 3.00. In FY2025, operating cash flow reached $91.9M and capital expenditures were $12.9M, generating $79.0M in free cash flow. Over the past five years, the company's share count increased 2.1%.

UFP Technologies carries a market capitalization of $2.26B and an enterprise value of $2.34B. The stock trades at a trailing P/E of 31.5x and a forward P/E of 21.8x, both above the median of its US-listed Healthcare peers (24.6x trailing and 17.3x forward). Its EV-to-EBITDA stands at 20.1x compared to the peer median of 12.0x, while its price-to-sales multiple of 3.6x sits below the peer median of 4.1x. Over the past year, UFPT returned 51.1% compared to a 16.8% return for the S&P 500, and over five years the stock gained 357.0% versus 83.0% for the index.

Wall Street coverage includes 1 Strong Buy, 1 Buy, and 2 Hold ratings. The mean price target is $355.00, which is 21.7% above the last close of $291.67. For the fiscal year ending December 31, 2026, analysts estimate EPS of $10.62 on revenue of $657.8M. For the next fiscal year, 4 analysts forecast EPS of $11.87 on revenue of $698.9M. UFP Technologies beat EPS estimates in each of the last 4 quarters, and its next earnings report is scheduled for November 2, 2026.

This page is an AI-written research summary of UFP Technologies, Inc. (UFPT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: UFPT income statement, UFPT balance sheet, UFPT key metrics, UFPT analyst forecast, UFPT chart. See the UFPT stock overview for the latest quote and news.